Enhancement of the solubility and the dissolution rate of candesartan cilexetil using microsponge technology was written by Nazar, Shaimaa;Alhammid, Abd. And the article was included in Asian Journal of Pharmaceutical and Clinical Research in 2018.Application of 145040-37-5 This article mentions the following:
The aim of the present study is to enhance the dissolution rate of candesartan cilexetil (CC) using microsponges. Candesartan is therapeutically a potent antihypertensive agent, but it suffers a major drawback of poor oral bioavailability, which is estimated to be 15% due to its low solubility in the gastrointestinal fluids and hepatic first-pass metabolism Eudragit-based microsponges were prepared by quasi-emulsion solvent diffusion method using different drug-polymer ratios (1:1 to 1:6), stirring speeds (250-750 rpm), and emulsifier concentrations (polyvinyl alc.) (0.05%-0.083% w/v). Differential scanning calorimetry (DSC) and Fourier transform IR spectroscopy (FTIR) study for CC, phys. mixtures of drug-polymer, and selected formula were investigated to estimate compatibility of CC with other used ingredients. All formulations were evaluated for particle size, production yield, and loading efficiency. The in vitro drug release study of optimized formulation was performed in phosphate buffer pH 6.8. The obtained results indicated that formula F3 which contains eudragit RS100 at drug:polymer ratio (6:1) was showed the smallest particle size with higher production yield and loading efficiency. DSC and FTIR study of the phys. mixtures of drug and polymer revealed no drug-polymer interaction. The results clearly confirm that the percentage of CC released at 30 min from F3, CC powder, and self-made tablet was 54%, 20.325, and 38.9%, resp. Microsponges technique was considered as a promising system to enhance the solubility and dissolution rate of poor-water soluble CC. In the experiment, the researchers used many compounds, for example, 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5Application of 145040-37-5).
1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division.Application of 145040-37-5
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem